Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 13
Semaglutide's modeled impact in Canada
A Canadian model projected broad semaglutide effects across conditions, costs and productivity, but its results are scenario estimates, not trial outcomes.
Semaglutide in forebrain organoids
A human-organoid study links semaglutide to less cholesterol-related neural stress, but it is not evidence of an Alzheimer's treatment.
Semaglutide in Pediatric Craniopharyngioma
A 20-patient retrospective series links semaglutide with lower BMI in adolescents with craniopharyngioma-related obesity, but cannot prove causation.
Tirzepatide lean-mass review
A 2026 review found that tirzepatide weight loss mostly came from fat, but lean mass also fell and muscle function was not measured.
Tirzepatide and NAION: New Record
A new French journal record names tirzepatide and NAION, but its no-abstract PubMed entry cannot establish clinical details or causation.
A Real-World Tirzepatide Cost Study
A claims-and-laboratory study compared persistence, outcome thresholds, and a defined cost-per-responder measure in US type 2 diabetes care.
New amylin agonists for obesity and T2D
Zenagamtide, eloralintide and CagriSema have early to late-stage results in obesity and type 2 diabetes. Their evidence is not interchangeable.
GLP-1 Marketing and the Lifestyle Message
A new report describes a shift in GLP-1 marketing. The medical context, access questions, and limits still matter.
GLP-1 and SGLT2 therapy in CKD
A large matched cohort study linked GLP-1 plus SGLT2 therapy with lower kidney and cardiovascular outcome rates in CKD. It cannot prove causation.
Incretin injections vs intensified insulin
A 2026 review found lower hypoglycaemia and weight with incretin-based injections versus intensified insulin, but the average HbA1c edge was small.
Semaglutide plus SGLT2 inhibitors in China
A Chinese real-world analysis described six-month metabolic outcomes in adults using semaglutide with an SGLT2 inhibitor.
Semaglutide and taste in mice
A 2026 mouse study found preserved taste responses during chronic semaglutide treatment, despite changes in sucrose-directed behavior.